VBL Therapeutics to Present at the UBS Global Life Sciences Conference MarketWatch (press release) Dr. Harats will also boundary the company's goals to advance the development of VB-201, which is currently in Phase 2 clinical trials in patients with psoriasis and patients with elevated hsCRP levels, As well as VB-111, which is in Phase ii clinical ... and more » Link To Article
No comments:
Post a Comment